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RESEARCH ARTICLE
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Abstract
It is well accepted that influenza A virus predisposes individuals to often more severe super-
infections with Streptococcus pneumonia. However, the mechanisms that lead to this syn-
ergy are not clearly understood. Recent data suggests that competent Th17 immunity is
crucial to clearance and protection from invasive pneumococcal disease of the lung. We
demonstrate that early influenza infection significantly reduced levels of pneumococcus
driven IL-12p70, IL-23 and IL-27 in human monocytes with significant impairment of IL-17A
and IFN-γ in HKSP-treated allogeneic mixed lymphocyte cultures. We also provide evidence
to suggest that the hemagglutinin component of the virus is at least partially responsible for
this downward pressure on IL-17 responses but surprisingly this suppression occurs despite
robust IL-23 levels in hemagglutinin-treated monocyte cultures. This study demonstrates
that influenza can directly affect the immunological pathways that promote appropriate
responses to Streptococcus pneumonia in human immune cells.
Importance
Influenza virus is highly contagious and poses substantial public health problems due to its
strong association with morbidity and mortality. Approximately 250,000–500,000 deaths are
caused by seasonal influenza virus annually, and this figure increases during periods of pan-
demic infections. Most of these deaths are due to secondary bacterial pneumonia. Influ-
enza-bacterial superinfection can result in hospitalisation and/or death of both patients with
pre-existing lung disease or previously healthy individuals. The importance of our research
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is in determining that influenza and its component haemagglutinin has a direct effect on the
classic pneumococcus induced pathways to IL-17A in our human ex vivo model.
Our understanding of the mechanism which leaves people exposed to influenza infection
during superinfection remain unresolved. This paper demonstrates that early infection of
monocytes inhibits an arm of immunity crucial to bacterial clearance. Understanding this
mechanism may provide alternative interventions in the case of superinfection with antimi-
crobial resistant strains of bacteria.
Introduction
The devastating synergism of bacterial pneumonia with influenza viral infections left its mark
on the world over the last century. Although the details of pathogenesis remain unclear, the
synergism is related to a variety of factors including pulmonary epithelial barrier damage
which exposes receptors that influence bacterial adherence and the triggering of an exagger-
ated innate immune response and cytokine storm, which further acts to worsen the injury.
Several therapeutics and combination therapies of antibiotics, anti-inflammatories including
corticosteroids and toll-like receptor modifiers, and anti-virals are being discussed. This mini
review summarizes recent developments in unearthing the pathogenesis of the lethal syner-
gism of pneumococcal co-infection following influenza, as well as addresses potential thera-
peutic options and combinations of therapies currently being evaluated.
There is considerable evidence from animal models, and clinical data from humans that
Influenza A virus (IAV) predisposes individuals to bacterial infection typically with capsular,
extracellular bacteria such as Streptococcus pneumoniae (S.p) and Staphylococcus aureus [1–3].
Influenza-bacterial superinfection can result in hospitalisation and/or death of both patients
with pre-existing lung disease or previously healthy individuals [4,5]. In the 1918 pandemic,
the late 1960’s pandemic, and the 2009 pandemic, the predominant bacterial co-pathogen was
Streptococcus pneumoniae [6–8]. Pandemics are not the only threat however, as approximately
one million deaths are caused by seasonal influenza virus annually [6,9], and most of these
deaths are due to secondary bacterial pneumonia [10]. In seasonal IAV, the most common co-
infecting bacteria is Staphylococcus aureus in adults, however in children, globally it is Strepto-
coccus pneumoniae [10], whilst in the U.S., Staphylococcus aureus has been implicated [11,12].
In addition, an important clinical manifestation of particular concern is the increase in antibi-
otic resistant strains of bacteria [2]. Understanding of the immunological mechanisms that
trigger susceptibility to bacterial disease during IAV infection may provide more treatment
strategies, particularly for superinfection with antibiotic resistant strains.
Although considerable progress has been made over the last decade, no real consensus has
been reached. Earlier studies have suggested that physiological damage to the respiratory epi-
thelium, along with increased adherence factors for S.p may be involved [1]. While these pro-
cesses are likely to contribute to more enhanced colonisation, recent research has pointed to
the role of immunological mechanisms in the susceptibility to invasive bacterial disease during
influenza infection [1,4,13,14]. A strong indication for a role of impaired immunological
responses have been suggested in mice such as reduced responsiveness of alveolar macro-
phages [15], and elevated levels of anti-inflammatory IL-10 [14,16]. Also, a neutrophil influx
caused by viral and bacterial toxins result in a cytokine storm leading to a destructive hyper
inflammatory response in mice [17].
Influenza inhibits human pneumococcal immunity
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Recently, Th17 cells have been identified as critical in the effective clearance of extracellular
capsular bacteria from the lung and further studies have revealed that IAV infection has been
shown to inhibit the Th17 response in mice [2]. Th17 cells are distinct from Th1 cells, which
control intracellular bacterial infections [18]. Th17 cells are the primary producers of interleu-
kin-17 (IL-17, also known as IL-17A), a pro-inflammatory cytokine [18], with a specific role in
the recruitment of neutrophils and macrophages [13]. It is well known that the cytokines,
transforming growth factor-β (TGF-β), IL-6 and IL-1β drive Th17 differentiation, while IL-23
conserves the expansion [19] and commitment to the Th17 lineage [20], thus increasing the
production of IL-17A [19]. Late viral induction of Type I and Type II interferons have been
shown to inhibit these essential Th17 responses to pneumococcus in mice [2,21]. Type I inter-
ferons include the subtypes IFN-α, of which there are thirteen distinct proteins, and IFN-β, of
which there is only a single protein [22]. Type I IFNs provide anti-viral protection by inhibit-
ing influenza replication and directing Th1 adaptive immunity [23].
A study found that the antiviral response of Type I IFNs predisposed mice to secondary
infections with S.p. Mice without functional IFN-α/β receptor (IFNAR) signalling were more
resistant to secondary bacterial pneumonia than mice with functional IFNAR signalling. Also,
mice deficient in type I IFN signalling are less susceptible than wild type mice to S.p. super–
infection at day 7 after influenza infection [2]. However, in contrast to these reports, it has been
shown that IFN-α expression prior to respiratory infection with S.p. improved the outcome of
pneumococcal infection in mice [24], and that IFNAR signalling can be crucial for S.p. bacterial
clearance [22,25–28]. There are also conflicting reports as to the effects of IFN-γ (Type II IFN)
during Streptococcus pneumoniae infection in mice. It has been shown that IFN-γ did not have a
protective role against Streptococcus pneumoniae, as IFN-γ receptor-deficient (IFN-γR-/-) mice
were found to have significantly fewer pneumococci in their lungs than wild-type mice, and
IFN-γ-/- mice had fewer colony-forming units present in the lungs than wild-type mice [29].
Another study found that in the presence of an influenza infection, IFN-γ produced in the lung
by T-cells inhibited macrophage-mediated bacterial clearance, which is essential in the clear-
ance of pneumococci, resulting in an increase in susceptibility to secondary bacterial infections
[3]. In contrast to these studies, it has been shown that IL-12 and IFN-γ can mediate protective
effects against Streptococcus pneumoniae by promoting neutrophil accumulation [30] and that
IFN-γ produced by neutrophils during Streptococcus pneumoniae infection was important in
host defence as mice deficient in IFN-γ had impaired bacterial clearance [31].
There have been significant studies in mice, but there is a need to add sufficiently to studies
in human models so that this complex relationship can be fully explored. Much of this work
has focused on the indirect effect of influenza host immune response to infection on the
impaired development of immune protection to bacterial disease. Our group has published
data which demonstrates that hemagglutinin (HA) from influenza virus directly down-regu-
lates bacterial LPS induced IL-12p35 in mice [4]. Although gram negative bacteria have been
associated with superinfection with influenza, the overwhelming evidence points to suscepti-
bility to gram-positive capsular bacteria such as S.p. during influenza infection [9]. In this
study, we therefore investigated if IAV infection or components specific to IAV, in addition to
anti-viral host responses could alter appropriate immunity to gram-positive pneumococcus in
humans. We also sought to investigate if immunomodulation was strain specific and we exam-
ined the responses in humans to H1N1 and H3N2 viruses.
In order to model the environment generated by influenza infection of the lung, in a previ-
ous study we comprehensively compared the maturation profiles (phenotypic expression,
cytokine production, apoptosis, and T cell proliferation) of untreated monocytes, IL-4-treated
dendritic cells (DCs), IFN-treated DCs, and DCs following co-culture with supernatant from
influenza infected lung epithelial cells. We found that direct influenza infection of monocytes
Influenza inhibits human pneumococcal immunity
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and monocytes cultured with supernatants from virally infected lung epithelial cells induce
distinct DC subsets compared with influenza infection of artificially generated IL-4-treated
DCs and IFN-treated DCs. We concluded that artificially generated DCs skewed immune
responses to influenza infection, whereas direct influenza infection of monocytes mimic those
generated from influenza infected epithelial cells supernatants and appear to more accurately
mimic those generated in vivo [32].
This model is based on comprehensive analysis of the signals provided by influenza infected
lung epithelial cells which will influence the extravasation and maturation of monocytes from
the periphery [32]. Monocytes directly infected by influenza are referred to as APCs. Thus, we
chose to infect primary human monocytes isolated from healthy volunteers directly with influ-
enza and assess the impact these infections have on innate responses to heat killed S.p in
human APCs. To ascertain the adaptive responses, a mixed lymphocyte reaction (MLR) was
used, which is commonly used in the investigation of T cell responses [4,32–38]. In this assay,
infected/treated APCs from one donor were co-cultured with human primary T cells from a
different donor resulting in an allogeneic response due to the mismatched major histocompat-
ibility complex (MHC) antigens. as per previous studies [4,32]. We show strong and consistent
evidence that live infection with Influenza virus down-regulates innate cytokines in HKSP-
treated cells such as IL-23 and IL-12p70 involved in Th17/Th1 generation. These responses
occur without elevated innate anti-inflammatory cytokines such as IL-10 and TGF-β, with
negligible IFNα/β protein production and with reduced IL-27 production.
We have further evidence to suggest that the HA component of IAV is at least partially
responsible for this downward pressure on IL-17 responses. Surprisingly this suppression by
HA occurs despite robust levels of IL-23 in HA treated APC cultures. This direct effect on the
classic IL-17A pathway by IAV and its components over and above the late induction of type-I
and type-II IFNs may further explain the overwhelming synergy between influenza and extra-
cellular capsular bacteria.
Materials and methods
Ethical statement
Ethical approval for this study was granted by Dublin City University’s Research Ethics
Committee.
Separation of peripheral blood mononuclear cells (PBMCs)
Buffy coats from healthy donors were obtained from the Irish Blood Transfusion service (at St
James’ hospital, Dublin). The peripheral venous blood (approximately 50 ml) was mixed with
5 ml of a 5% solution of EDTA and diluted 1:2 with HBSS containing 1% FBS, and 10 μM
HEPES buffer. This diluted blood was layered onto 14 ml of density gradient medium Lym-
phoprepTM (Axis-shield, Norway) and centrifuged at 400 x g for 25 minutes (with accelerator
and break switched off). With blood components separated according to density, the buffy
coat layer was removed and cells were washed twice with 10 ml of complete RPMI (cRPMI)
(supplemented with 10% FBS, 10 mM HEPES, and 100U penicillin/ml). Finally, cells were fil-
tered through a 40 μM filter and diluted to required cell number per ml.
Separation, purification and depletion of cell subsets from PBMCs using
microbead separation
Cells were purified from PBMCs using magnetic microbeads by MACS (Miltenyi Biotec,
UK). PBMCs were resuspended in MACs buffer (sterile PBS supplemented with 0.5%
Influenza inhibits human pneumococcal immunity
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bovine serum albumin (BSA) and 2 μM EDTA) and incubated with target-cell specific anti-
bodies conjugated to magnetic microbeads according to the manufacturer’s instructions.
Following incubation, cells were washed with MACs buffer. For positive selection of CD14+
or CD3+ cells, cell suspension was applied to an LS column attached to a magnet. The
column was washed 3 times with 3 ml of MACs buffer. The positively labelled cells were
flushed out of the column with a plunger in the absence of magnetic force. The initial “flow
through” and wash step were used as the CD14+ cell depleted fraction. CD14+ and CD3+
cells were isolated from different donors. CD3+ T cells at a density of 2x105 cells/ml were
co-cultured with 106 cells/ml of treated CD14+ cells and incubated for a further 24 h at 37˚C
and 5% CO2.
Viruses and infection experiments
Isolated CD14+ cells at a density of 106 cells/ml were exposed to Heat Killed S.p (HKSP) sero-
type I (ATCC #6301, VA, USA), (107 CFU) (cultured as below) or Heat Killed Streptococcus
pneumoniae (HKSP) (107 CFU) (Invivogen), live H1N1 (Puerto-Rico/8/34) or H3N2 (Wis-
consin/67/2005, A/Panama/2007/99 NIBSC, UK, and A/Uruguay/716/2007), (4.9 PFU/ml),
H1N1 HA (Puerto-Rico/8/34) or H3N2 HA (A/Wisconsin/67/2005 and A/Uruguay/716/2007)
(1 μg ml-1 or 3 μg ml-1), alone or in combination with HKSP for 24 h.
Culture of Streptococcus pneumoniae
Lyophilised Streptococcus pneumoniae (ATCC #6301, serotype I) pellet was resuscitated with 1
ml of brain heart infusion broth (BHIB) and transferred to 100 ml BHIB for overnight culture
at 37˚C. Streak plates were prepared and gram positive cocci were confirmed by gram stain.
The culture was incubated until OD600 0.633, after which it was centrifuged at 3,000 x g for 10
min, washed three times in sterile pyrogen-free PBS and resuspended in 50 ml PBS. The num-
ber of bacteria in the final suspension was determined by plating 10-fold serial dilutions onto
agar plates. Heat inactivation was accomplished in a water bath at 60˚C for 90 min. Streak
plates were prepared and no live bacteria were detected after the heat killed Streptococcus pneu-
moniae suspension was plated and incubated overnight. Aliquots of pneumococci were pre-
pared and kept frozen at −70˚C.
Poly(I:C) stimulations
Poly(I:C) (1 μg/ml) was mixed with 100 ul LyoVecTM solution and incubated at RT for at least
15 minutes. Isolated CD14+ cells at a density of 106 cells/ml were stimulated Poly(I:C) and Lyo-
VecTM solution (Invivogen) and incubated for 24 h at 37˚C.
qPCR
Total RNA was isolated by using either the RNeasy mini kit (Qiagen), including DNase diges-
tion (RNase-free DNase kit; Qiagen) or the RNeasy Plus mini kit (Qiagen). Total RNA was
reverse transcribed into cDNA (GoScript Reverse Transcription System; Promega). cDNA
samples were amplified using the Lightcycler Nano (Roche Diagnostics) and Faststart Essential
DNA Probes Master System (Roche Diagnostics) with RealTime Ready Assays (Roche Diag-
nostics). Expression of IFN-α (Assay ID: 145795), IFN-β (Assay ID: 145797), and GAPDH.
The chosen IFN-α probes detect a sequence which is common to all IFN-α subtypes. Gene
expression was normalised to expression of the reference gene GAPDH.
Influenza inhibits human pneumococcal immunity
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Enzyme-linked immunosorbent assay
Supernatant from treated cells (as above) was used to detect for the following cytokines using
ELISA kits; IL-23, IL-12p70 (eBioscience/Biosciences), IL-6, IL-1β, IL-27, TGF-β, IL-10, IFN-
α, and IFN-β (R&D systems) were used to quantify cytokine levels in supernatants according
to manufacturer’s protocol. At least 3 experimental repeats of each treatment were analysed
for each cytokine/donor.
Apoptosis studies
Treated CD14+ cells were stained with annexin V Apoptosis Detection Kit I (BD-Pharmingen)
according to manufacturer’s protocol and detected using FACSCaliburTM Flow Cytometer/
CellQuest software (BD-Biosciences). CD14+ cells treated for 24 h as outlined above, were dual
stained with FITC annexin V and propidium iodide. The percentages of viable, necrotic/late
apoptotic, early apoptotic cells after treatments were ascertained using flow cytometry for 3
independent donors.
Western blot
Treated cells were lysed for 10 min on ice in suspension buffer (0.1 M NaCl, 0.01 M Tris-Cl (pH
7.6), 0.001 M EDTA (pH 8.0), 1 μg/ml leupeptin, 1 μg/ml aprotinin, 100 μg/ml PMSF). An equal
volume of 2 X SDS gel loading buffer (100 mM Tris-Cl (pH 7.6), 4% (w/v) SDS, 20% (w/v) glyc-
erol, 10% (v/v) 2-mercaptoethanol 0.2% bromophenol blue) was immediately added to the cell
suspension followed by sonication for 20 s with 1-s pulses (40/output, 200 W). The lysate was clar-
ified by centrifugation at 12,000 x g for 10 minutes at room temperature followed by boiling at
95˚C for 5 min. Approximately equal numbers of cell equivalents were loaded and SDS-PAGE
was performed using 10% (v/v) resolving gels and 5% (v/v) stacking polyacrlyamide gels. Proteins
were transferred to 0.45 μm nitrocellulose membranes. Membranes were blocked in TBS+5%
milk for 1 h at room temperature, then probed with Mouse Anti-human-β-actin clone AC-15
(Sigma-Aldrich) in TBS+5% milk for 2 h at room temperature or overnight at 4˚C. Membranes
were washed and incubated with Goat anti-mouse IgG, Alkaline Phosphatase conjugated anti-
body (Promega) in TBS+5% milk for 1 h at room temperature. Membranes were washed and
incubated in BCIP (Sigma-Aldrich) reagent for 5 min at room temperature and photographed.
Statistical analysis
Statistical analyses were performed using GraphPad Prism version 6.0 for windows and Mac
(GraphPad Software). Where stated, data was normalised by setting untreated sample readings to
~1 and comparing treated sample readings to that value, thus providing relative concentrations.
Data has been normalised to allow for the presentation of data for multiple human donors; this is
due to donor-to-donor variability in relation to actual concentration of cytokines produced. A
One-way ANOVA was fitted to the data and comparisons of interest were made using a Sidak test
to adjust for multiple testing, using a 5% significance interval; p-values less than 0.05 were consid-
ered significant and are represented as follows: p<0.05, p<0.01, p<0.001, p<0.0001.
Results
Influenza A virus infection inhibits innate immune responses in human
APCs treated with HKSP
Experimental animal models and clinical data from humans strongly support IAV as a predis-
posing agent to more severe bacterial infection with S.p [1]. Reports have suggested that late
Influenza inhibits human pneumococcal immunity
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antiviral immunity while important in IAV clearance, can promote increased susceptibility to
secondary bacterial infection [2,3]. However, this may not fully explain the remarkable specific
synergy between IAV and superseding capsular, gram-positive bacteria. We separated periph-
eral blood mononuclear cells (PBMCs) from buffy coats from healthy human donors and have
demonstrated that IAV infection inhibits innate responses in human APCs treated with HKSP
24 hours post-infection. We found that the H3N2 subtype of IAV significantly inhibited levels
of IL-6 in pneumococcus-treated primary human monocytes (Fig 1A) (n = 5). Two subtypes
of IAV (H1N1 and H3N2) significantly inhibited pneumococcus driven Th17 polarizing IL-23
(n = 7) (Fig 1A) and the Th1 polarizing IL-12p70 (n = 12) (Fig 1B). This reduction was not
observed for the Th17 inducing cytokine, IL-1β (n = 11) (Fig 1C). We also found that IL-27
(n = 10) was induced by pneumococcus and this response was inhibited by IAV (Fig 1D). A
reduction was not observed for the anti-inflammatory cytokine, IL-10 (n = 9) (Fig 1E), which
has been shown to inhibit Th17 responses [39], or the multi-functional cytokine, TGF-β
(n = 8) (Fig 1F).
Influenza A virus significantly inhibits Th17/Th1 innate polarizing
cytokines despite negligible or undetectable IFN-α or IFN-β message RNA
or protein
Much of the previous studies in mice show that it is late viral Type I interferons that are
responsible for inhibition of essential Th17 responses [2,21]. To investigate if the downward
pressure on polarizing cytokines was due to the production of Type I IFNs, we used qPCR to
detect for the presence of IFN-α and IFN-β message. In humans, there are 13 different IFN-α
Fig 1. Live IAV attenuates innate cytokines in HKSP-treated cells. The levels of (A) IL-6, IL-23, (B) IL-12p70, (C) IL-1 β, (D) IL-27, (E) IL-10, and (F) TGF-β,
secreted by CD14+ cells following 24 h treatment with HKSP, live H1N1 or H3N2 alone or in combination with HKSP (or untreated as a control) were determined
by ELISA. Each column represents normalised mean cytokine levels + SEM of at least 3 experimental repeats of each treatment/donor. Each ELISA represents
normalised results from multiple donors: (A) IL-6 (n = 5), IL-23 (n = 7), (B) IL-12p70 (n = 12), (C) IL-1 β (n = 11), (D) IL-27 (n = 10), (E) IL-10 (n = 9), and (F)
TGF-β (n = 8). Statistical analyses were performed to compare cytokine levels in cells exposed to HKSP versus cells exposed to live H1N1 or H3N2 in combination
with HKSP by fitting a One-way ANOVA to the data and using a Sidak test to adjust for multiple testing (p<0.05, p<0.01, p<0.001, p<0.0001).
https://doi.org/10.1371/journal.pone.0203521.g001
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subtypes, to ensure capture of all subtypes, we implemented rigorous bioinformatics searches to
ensure chosen probes and primers amplified a region of the mRNA sequence which was common
to all subtypes. IFN-α was undetectable in three out of four donors, with very low transcription
levels detectable in just one donor, compared to samples treated with Poly(I:C) (n = 4) (Fig 2A).
Very low levels of IFN-β amplification was detected in all samples compared with samples treated
with Poly(I:C) (Fig 2B). To establish the protein levels of IFN-α and IFN-β in supernatants, we
used ELISA. IFN-α and IFN-β were induced strongly in Poly(I:C) treated cells compared to other
cells (Fig 2C and 2D). IFN-α was detectable in all cells, apart from those treated with HKSP, and
co-treated with H3N2 and HKSP (Fig 2C). IFN-β was detectable in very low amounts in all cells
(Fig 2D). IFN-α has been found to be produced 3 days post-influenza infection, peaking at day 5
in mice [2]. The reason for such late anti-viral IFN responses has been attributed to the influenza
viral protein, non-structural protein 1 (NS1), which contributes to the evasion of the hosts innate
immune responses by blocking NF-κB, IRF3, and IRF7 activation, resulting in the inhibition of
Type I IFNs [40]. In the absence of NS1, IFN-β mRNA message has been detected as early as 3 hrs
post-infection [41], in addition it has previously been shown that baseline IFN-β protein levels are
not sufficient to inhibit Th17 responses in humans [42].
Inhibition of Th17/Th1 innate polarizing cytokines are not due to cell
death or shutdown of protein synthesis
To ensure that the inhibition of innate Th17/Th1 polarising cytokines in human monocytes
(APCs) is not due to cell death or protein synthesis shutdown, an apoptosis study and western
blot were performed, respectively. The effects on the Th17 and Th1 cytokines were detected
within 24 h of simultaneous co-culture and were not due to cell death (Fig 3A). Host protein syn-
thesis shutdown did not occur as we detected the presence of the house-keeping protein, β-Actin
(Fig 3B). This corresponds with the selective nature of the viral inhibition of cytokine levels. The
crucial role for IL-17 in HKSP immunity is unquestionable [1,2]. Thus, it would appear, in this
ex vivo human model, that influenza infection directly affects immune pathways important to
the resolution of HKSP infection which is not due to cell death or protein synthesis shutdown.
Influenza A virus inhibits polarisation of human allogeneic T cells towards
Th17 in HKSP-treated cells
To investigate the adaptive response, the use of allogeneic APC-T cell co-cultures was imple-
mented as described before [4,32]. The allogeneic APC-T cell co-cultures also demonstrated
Fig 2. Modulation by IAV of innate and adaptive responses to Pneumococcus is not due to Type I IFN production. (A) IFN-α (n = 4) and (B) IFN-β (n = 3) mRNA
production in CD14+ cells following 24 h treatment with HKSP, live H1N1 or H3N2 alone or in combination with HKSP (or untreated as a control), or 1 μg Poly(I:C)
transfected with LyoVec solution. mRNA expression of IFN-α, IFN-β, and GAPDH from infected and control treatments was determined by qPCR. The level of IFN-α
(n = 3) (C) and IFN- β (n = 3) (D) protein secreted by CD14+ cells following 24 h treatment with HKSP, live H1N1, H3N2 alone or in combination with HKSP or Poly(I:
C) (or untreated as a control) were determined by ELISA.
https://doi.org/10.1371/journal.pone.0203521.g002
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that IAV infection had a profound effect on IL-17A production in response to HKSP treatment
(n = 9) and IFN-γ (n = 13) (Fig 4A and 4B) indicating impaired Th17/Th1 responses in these
co-cultures. Furthermore, the attenuation of the innate and adaptive IL-17 and IFN-γ pro-
inflammatory pathways (Fig 4A and 4B) cannot be associated with increased innate expression
of the anti-inflammatory cytokines IL-10 and TGF-β (n = 3) as no statistically significant
increases were observed (Fig 4C). Although, a slight but nonsignificant increase of IL-10 was
noted in cell supernatant co-treated with HKSP and H1N1, inhibition was also observed in
cells co-treated with HKSP and H3N2 where no elevation of IL-10 was detected.
Influenza HA selectively modulates human innate immune responses to
pneumococcus treatment
We had previously observed that influenza HA down regulated LPS induced IL-12p70 in mice
and that subtype specific anti-HA could restore these responses in murine derived bone
Fig 3. Modulation by IAV of innate and adaptive responses to Pneumococcus is not due to cell death or host protein synthesis
shutdown. (A) CD14+ cells treated for 24 h with HKSP, live H1N1 or H3N2 alone or in combination with HKSP (or untreated as a
control) were dual stained with FITC annexin V and propidium iodide. The percentages of viable, necrotic/late apoptotic, and early
apoptotic cells after treatments were ascertained using flow cytometry. Each column represents mean % cell number + SEM of 3
independent donors. (B) Lysates from CD14+ cells treated for 24 h as outlined in (A) above, were prepared and analysed by Western
blot for β-actin levels. Western blot is a representative of 2 independent repeats with different donors.
https://doi.org/10.1371/journal.pone.0203521.g003
Fig 4. Live IAV attenuates adaptive cytokines in pneumococcus-treated cells. (A) IL-17A, (B) IFN-γ, (C) IL-10, and TGF-β, levels induced in allogeneic CD3+ T
cells, co-cultured with CD14+ cells following 24 h treatment with HKSP, live H1N1 or H3N2 alone or in combination with HKSP (or untreated as a control) were
determined by ELISA. Each column represents normalised mean cytokine levels + SEM of at least 3 experimental repeats of each treatment/donor. Each ELISA
represents normalised results from multiple donors: (A) IL-17A (n = 9), (B) IFN-γ (n = 13), (C) IL-10 and TGF-β (n = 3). Statistical analyses were performed to
compare cytokine levels in cells exposed to HKSP versus cells exposed to live H1N1 or H3N2 in combination with HKSP by fitting a One-way ANOVA to the data
and using a Sidak test to adjust for multiple testing (p<0.05, p<0.01, p<0.001, p<0.0001).
https://doi.org/10.1371/journal.pone.0203521.g004
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marrow-derived dendritic cells (BMDCs) [4]. We were interested in establishing if this compo-
nent was involved in the suppression of pneumococcal responses by IAV in these human cul-
tures. In contrast to live infection, H1N1 HA actually inhibited pneumococcus induced IL-6
(n = 3), whereas H3N2 HA did not (Fig 1A). Strikingly, HA actually induced robust levels of
IL-23 (n = 4) (Fig 5A) when combined with HKSP. Similarly, to live infection, both subtypes
of IAV HA significantly attenuated HKSP induced IL-12p70 (n = 3) (Fig 5B), with a significant
down-regulation of pneumococcus induced IL-27 (n = 6) by H1N1 HA (Fig 5C). Also in con-
trast to live infection, HA enhanced levels of IL-1β (n = 4) (Fig 5D) when combined with
HKSP, although this was not statistically significant. Interestingly, H3N2 HA decreased levels
of IL-10 (n = 4) (Fig 5E) and H1N1 HA increased levels of TGF-β (n = 3) (Fig 5F) in combina-
tion with HKSP.
Influenza HA inhibits adaptive human responses to pneumococcus
Despite the significantly high levels of IL-23 and increased levels of IL-1β, we see a marked
reduction in pneumococcus driven IL-17A and IFN-γ from Human allogeneic APC-T cell co-
cultures when monocytes were primed with HA prior to co-culture. We see a reduction in
pneumococcus driven IL-17A (n = 3) by H3N2 HA (3μg ml-1) and a reduction in pneumococ-
cus driven IFN-γ (n = 3) by both H1N1 and H3N2 HA (Fig 6A). Unlike live infection, certain
doses of HA were shown to increase the anti-inflammatory cytokines IL-10 and TGF-β (n = 6)
Fig 5. Influenza HA specifically attenuates innate cytokines in HKSP-treated cells. The levels of (A) IL-6, IL-23, (B) IL-12p70, (C) IL-27, (D) IL-1β, (E) IL-10 and (F)
TGF-β secreted by CD14+ cells following 24 h treatment with HKSP, H1N1 HA (1μg ml-1 or 3 μg ml-1) or H3N2 HA (1μg ml-1 or 3 μg ml-1) alone or in combination
with HKSP (or untreated as a control) were established by ELISA. Each column represents normalised mean cytokine levels + SEM of at least 3 experimental repeats of
each treatment/donor. Each ELISA represents normalised results from multiple donors: (A) IL-6 (n = 3), IL-23 (n = 4), (B) IL-12p70 (n = 3), (C) IL-27 (n = 6), (D) IL-1β
(n = 4), (E) IL-10 (n = 4), and, TGF-β (n = 3). Statistical analyses were performed to compare cytokine levels in cells exposed to HKSP versus cells exposed to H1N1 HA
or H3N2 HA (1μg ml-1 or 3 μg ml-1) in combination with heat-inactivated HKSP, by fitting a One-way ANOVA to the data and using a Sidak test to adjust for multiple
testing (p<0.05, p<0.01, p<0.001, p<0.0001).
https://doi.org/10.1371/journal.pone.0203521.g005
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(Fig 6B), although this was not statistically significant. However, these increases did not always
correlate to doses of HA associated with down regulation of innate and adaptive IL-17 and
IFN-γ pro-inflammatory pathways. The exclusion of an anti-inflammatory role is also sup-
ported by previous studies in mice where blocking IL-10 did not restore IL-12p70 levels in
murine BMDCs [4]. These results suggest that HA may directly interfere with the IL-17 path-
way without targeting the IL-23 or the IL-1β pathway.
Discussion
Both clinical and animal data suggest that the greatest susceptibility to S.p infection occurs at
the initiation of the recovery stage from IAV; approximately 7 days post influenza infection
[1]. Researchers have therefore based their assumptions that it is the immune response to the
virus occurring at this stage that contributes to the lethal synergy. This has been supported by
several recent studies which suggest that the late type-I and type-II interferon response to the
initial influenza infection render co-colonised hosts vulnerable to this lethal synergism [2,3].
However, during the 1918 pandemic, deaths were already occurring by day 7 [43]. While this
antiviral response is likely to be an extremely important mechanism in influenza–pneumococ-
cus co-pathogenesis, there may be other aspects of the interaction which could account for this
synergism. Furthermore, this late anti-viral response may not be responsible for the increased
susceptibility in children who have asymptomatic S.p carriage prior to influenza infection [44].
Recently, in an attempt to model what might occur in children, infant mice were colonised
with S.p and subsequently infected with influenza. Within 6 days of IAV infection bacterial
numbers had increased by 300-fold in the lung of co-infected animals [45], suggesting that
synergistic mechanisms may also be occurring at earlier time points in infection. Additionally,
an epidemiological study in humans of the incidence of bacterial co-infection in the 2009
influenza pandemic found that on average individuals developed co-infections, within the first
6.2 days of influenza infection. The authors suggest that co-infections coincide with high influ-
enza viral shedding (2–3 days post-influenza infection), but may also occur simultaneously or
shortly after influenza infection [46].
This is the first study to demonstrate an inhibitory effect of live IAV infection on IL-17A
production in untreated allogeneic and pneumococcus-treated cells in humans. This study is
Fig 6. Influenza HA specifically attenuates adaptive cytokines in HKSP-treated cells. (A) IL-17A, IFN-γ, (B) IL-10 and TGF-β levels induced in allogeneic CD3+
T cells, co-cultured with CD14+ cells following 24 h treatment with HKSP, H1N1 HA (1μg ml-1 or 3 μg ml-1) or H3N2 HA (1μg ml-1 or 3 μg ml-1) alone or in
combination with HKSP (or untreated as a control) were determined by ELISA. Each column represents normalised mean cytokine levels + SEM of at least 3
experimental repeats of each treatment/donor. Each ELISA represents normalised results from multiple donors: (A) IL-17A (n = 3), (B) IFN-γ (n = 3), (C) IL-10 and
TGF-β (n = 6). Statistical analyses were performed to compare cytokine levels in cells exposed to HKSP versus cells exposed to H1N1 HA or H3N2 HA (1μg ml-1 or
3 μg ml-1) in combination with heat-inactivated HKSP, by fitting a One-way ANOVA to the data and using a Sidak test to adjust for multiple testing (p<0.05,
p<0.01, p<0.001, p<0.0001).
https://doi.org/10.1371/journal.pone.0203521.g006
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also novel in that it identifies an inhibitory effect on IL-17A induction which is not dependent
on type-I or type-II IFN production but involves at least one significant viral component. In
cells co-treated with HKSP and IAV, we have observed no IFN-α and low levels of IFN-β mes-
sage in qPCR analyses. Low levels of IFN-α protein were detected in cells co-treated with
H1N1 and HKSP, but no IFN-α protein was detected in cells co-treated with H3N2 and
HKSP. Levels of IFN-β protein was detected in cells co-treated with HKSP and IAV, however
these were below levels in untreated cells. The presence of low levels of IFN-α protein in cells
co-treated with HKSP and H1N1 cannot be responsible for the inhibition of HKSP responses
as little to no IFN-α protein was detected in cells co-treated with HKSP and H3N2, where the
same inhibition occurs. The presence of IFN-β protein cannot explain the attenuation of the
Th1 and Th17 responses as these are below basal levels, which were present in all cells, includ-
ing untreated and HKSP treated cells, in which we observed robust Th17 innate immune
responses. In addition, a previous study in human cells demonstrated that basal levels of IFN-β
are insufficient to inhibit Th17 responses [42]. Of note, we have observed that IAV inhibits
pneumococcus-induced IL-27. IL-27 is a cytokine of much interest as it was shown to contrib-
ute to Th1 immunity by synergising with IL-12 in the production of IFN-γ [47]. However,
more recent studies have shown that IL-27 has the ability to supress Th1, Th2, and Th17
responses in both humans and mice [42,48,49]. A more recent study in mice demonstrated
that influenza-induced IL-27 led to a predisposition to secondary pneumococcal pneumonia
due to suppression of IL-17A [41]. A similar result was also demonstrated in mice infected
with influenza and Staphylococcus aureus [50]. In human cells, it was also observed that IL-27
inhibited IL-17A production and decreased the production of IL-23, IL-1β and IL-6 [41]. In
contrast in our study, we observed a much stronger induction of IL-27 by HKSP than by IAV
and an inhibition of IL-27 by IAV infection. These discrepancies may be due to the fact that
we do not detect strong Type I IFN responses in IAV infected cells. It has been shown that
IAV induces IL-27 in a IFNAR-dependent manner [41], which occurs with late-viral immune
responses (32), subsequently, IL-27 can inhibit Th17 responses in a STAT1-dependent manner
[51,52]. However, in the absence of STAT1, IL-27 has been shown to be involved in the differen-
tiation of Th17 by inducing pSTAT3 in mice [53]. So, in the absence of Type I IFN signalling,
IL-27 may enhance Th17 production. Indeed, it is possible that the reduction of HKSP induced
IL-27 may contribute to the overall inhibition of the Th17 response. Due to the conflicting data
regarding IL-27 and its role in the Th17 pathway, further studies are required in order to make
robust conclusions regarding this cytokine. The inhibition of Th17 cytokines by IAV occurred
in the absence of elevated levels of TGF-β, which can have either pro or anti-inflammatory
effects [54,55]. TGF-β is neither induced by HKSP or inhibited by IAV; as TGF-β remains at
basal levels despite treatment, TGF-β is not exerting any anti-inflammatory effects.
In our previous study, we demonstrated that IAV hemagglutinin inhibited lipopolysaccha-
ride-induced IL-12p70 in murine derived bone marrow-derived dendritic cells [4]. In this
study, we sought to investigate if hemagglutinin, a major component of IAV, which is also
used in seasonal influenza vaccines, could be responsible for any of the inhibition observed in
this human model. We found that although IAV inhibited HKSP induced IL-23, HA actually
induced robust levels of IL-23, despite this IL-17A was inhibited by H3N2 HA and reduced by
H1N1 HA. HA also induced IL-1β when combined with HKSP. These results also suggest that
it is the selective suppression of IL-6 by H1N1 HA that contributes to the reduced IL-17A
responses in human primary T cells. Several cytokines contribute to Th17 differentiation, how-
ever IL-23 has been most extensively studied as being key to the growth and survival of Th17
cells expressing IL-17A [56]. Clearly other cellular pathways that contribute to IL-17A need to
be explored. Support for our findings is also evident in the recent reports that demonstrate
that influenza HA or modified versions thereof can inhibit IL-17A and IL-6 production in
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mice with subsequent beneficial effects on collagen-induced arthritis [57]. Interestingly,
authors did not present data for IL-23 in these studies. In addition, while HA exerts its effects
independently of IL-23, it is clear from the live infection that inhibition of IL-23 is also
involved. As the effects are observed within 24 hours of infection it is likely that other compo-
nents of the virus are contributing directly to IL-23 suppression and these results suggest that
the innate immune suppression is more extensive with the whole virus infection contributing
to perhaps greater susceptibility during live influenza infection. We also observe that H3N2
virus appears to be more immunosuppressive than H1N1 virus, however the H1N1 HA is
more immunosuppressive than the H3N2 HA. A study found that there is higher neuramini-
dase (NA) activity in H3N2 viruses than in H1N1 viruses [58], which leads to higher mortality
from secondary bacterial pneumonia [59]. This may be why the H3N2 virus appears to exert a
stronger level of inhibition compared to the H1N1 virus. The findings of this study are novel
compared to previous studies in that the results suggest that early influenza infection may
inhibit Th17 pathways in humans in the absence of Type I IFN, which may also be relevant to
enhanced bacterial colonisation. Furthermore, the partial association of HA, which is a major
component of IAV vaccines [60–64], with IL-17A down-regulation may have implications for
the recommended use of multiple vaccines as a whole and particularly combined influenza
and pneumococcal vaccines [65]. As suggested by Irish Health Service Executive (HSE)
(https://www.hse.ie/eng/health/immunisation/pubinfo/flu-vaccination/faq.pdf), the current
protocol for administering the influenza vaccine and pneumococcal conjugate vaccine (PCV)
to children is to separate administration of vaccines by 1 week. Whereas the pneumococcal
polysaccharide vaccine (PPV), which is administered to adults can be administered concur-
rently with the influenza vaccine, albeit at different sites. We would recommend that adminis-
tration at different sites should continue to prevent any interference between influenza and
pneumococcus vaccines from occurring.
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